gsk-2816126 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

gsk-2816126 has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for gsk-2816126 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

ArticleYear
PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 01-01, Volume: 24, Issue:1

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Enhancer of Zeste Homolog 2 Protein; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridones; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2018